Last Updated: 21 July 2022
Butterfly Network, Inc., a Delaware, United States of America corporation (“Butterfly” or the “Company”), is committed to preventing slavery and human trafficking in its business activities and its supply chain.
This statement is made pursuant to Section 54 of the Modern Slavery Act 2015 of the United Kingdom for the financial year ending December 31, 2021. This statement applies to Butterfly Network, Inc. and its wholly-owned subsidiaries.
Butterfly is a medical device manufacturer/health technology company based in the United States. The Company created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected.
Butterfly’s supply chains include the sourcing of raw materials, the purchase of third-party products and the use of distribution networks related to the manufacture of its products. We relay our expectations in relation to compliance with applicable laws to suppliers via our third party agreements.
Our Code of Business Conduct and Ethics (the “Code”) was adopted to promote ethical conduct and compliance with applicable laws, rules and regulations. All employees are encouraged to report violations of the Code to the Corporate Compliance Officer, the chairperson of the Audit Committee of the Board of Directors or to the Company’s Whistleblower Compliance Hotline.
Butterfly plans to undertake training to educate and inform employees about the risks of modern slavery and human trafficking. We intend to continue to review our policies and processes to further our commitment to preventing slavery and human trafficking in our business activities and supply chain.